Liquidia Corporation filed its quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2026, with the Securities and Exchange Commission on November 10, 2026.
Key Highlights
- Shares outstanding: As of October 28, 2026, there were 90,106,442 shares of common stock outstanding.
- Exchange listing: Common stock, $0.001 par value per share, is listed on The Nasdaq Stock Market LLC under the symbol LQDA (NASDAQ:LQDA).
- Filer classification: Liquidia is classified as a non-accelerated filer and is neither a smaller reporting company nor an emerging growth company, according to the filing.
- Reporting period: The filing covers the fiscal quarter ended September 30, 2026, with comparative financial statements for the three and nine months ended September 30, 2026 and 2025.
- Key product: The filing identifies YUTREPIA as a currently approved commercial product, with L606 described as a product candidate subject to ongoing regulatory review.
- Forward-looking statements: The filing states that forward-looking statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and involve "known and unknown risks, uncertainties and other important factors."
Liquidia's Third-Quarter 2026 Disclosure: YUTREPIA, L606, and Key Financial Statements
Liquidia Corporation, a Delaware corporation headquartered at 419 Davis Drive, Suite 100, Morrisville, North Carolina, filed its Form 10-Q for the quarter ended September 30, 2026, disclosing condensed consolidated financial statements covering both three-month and nine-month periods ending September 30, 2026 and 2025. The filing was submitted under Commission File Number 001-39724. As of October 28, 2026, the company reported 90,106,442 shares of its common stock outstanding.
According to the filing, Liquidia's principal commercial product is YUTREPIA, and the company described ongoing activity related to L606, a product candidate for which the company referenced potential final FDA approval and commercialization as forward-looking items. The filing noted a Settlement Agreement with United Therapeutics Corporation as a defined agreement, acknowledging costs and commercial obligations arising from it. The company also referenced third-party device arrangements, including Plastiape's RS00 Model dry powder inhaler used for YUTREPIA administration, and a nebulizer for L606 delivery involving Vectura's device.
The quarterly report's financial section includes condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, condensed consolidated statements of operations and comprehensive loss, statements of stockholders' equity and deficit, and cash flow statements for the nine months ended September 30, 2026 and 2025. The filing confirmed that all required Interactive Data Files were submitted electronically, and that the registrant had filed all reports required under the Exchange Act during the preceding 12 months. The company confirmed it is not a shell company.
What Was Disclosed
Liquidia Corporation filed its Form 10-Q for the quarter ended September 30, 2026, reporting 90,106,442 shares outstanding as of October 28, 2026. The filing covers commercial activity related to YUTREPIA and regulatory progress on L606, with full condensed consolidated financial statements included.




Please wait processing your request...